Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44399   clinical trials with a EudraCT protocol, of which   7411   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,399 result(s) found. Displaying page 1,786 of 2,220.
    «« First « Previous 1782  1783  1784  1785  1786  1787  1788  1789  1790  Next» Last»»
    EudraCT Number: 2018-004201-33 Sponsor Protocol Number: IMMU-132-09 Start Date*: 2019-08-16
    Sponsor Name:Immunomedics, Inc.
    Full Title: Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Nega...
    Medical condition: Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006198 Breast cancer recurrent PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) DE (Completed) NL (Completed) ES (Ongoing) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002125-30 Sponsor Protocol Number: 2012LRDVDCM Start Date*: 2012-10-24
    Sponsor Name:UZLeuven
    Full Title: Vitamin D supplementation in cutaneous malignant melanoma outcome
    Medical condition: cutaneous malignant melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2015-001972-23 Sponsor Protocol Number: 2015-001972-23 Start Date*: 2015-06-29
    Sponsor Name:Tampere University Hospital
    Full Title: Randomized study to compare vaginal misoprostol to oral misoprostol in inducing labor
    Medical condition: Pregnant women; induction of labor
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001237-17 Sponsor Protocol Number: PETPLAQUE Start Date*: 2004-09-10
    Sponsor Name:Raitakari Olli
    Full Title: Imaging the vulnerable carotid artery atherosclerotic plaque
    Medical condition: carotid atherosclerosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-002734-41 Sponsor Protocol Number: P091205 Start Date*: Information not available in EudraCT
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title:
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-000450-49 Sponsor Protocol Number: None Start Date*: 2006-03-07
    Sponsor Name:Helsinki University Central Hospital
    Full Title: Pharmacokinetics of transdermal fentanyl in normal weight and cachectic patients with cancer related pain
    Medical condition: Cancer of any kind
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003057-42 Sponsor Protocol Number: CAO/ARO/AIO-16 Start Date*: 2018-02-23
    Sponsor Name:Univeristy Hospital Tuebingen
    Full Title: Organ preservation in locally advanced rectal cancer by radiochemotherapy followed by consolidation chemotherapy. A prospective phase II pilot trial of the German Rectal Cancer Study Group
    Medical condition: Locally advanced rectal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038046 Rectal cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038050 Rectal cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-000279-16 Sponsor Protocol Number: TRALG 1/02 Start Date*: 2007-06-07
    Sponsor Name:Sahlgrenska University Hospital
    Full Title: Phase III Clinical Study of Allogeneic Stem Cell Transplantation with Reduced Conditioning (RICT) versus Best Standard of Care in Acute Myeloid Leukemia (AML) in First Complete Remission
    Medical condition: Acute myeloid leukemia in first complete remission
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005286-69 Sponsor Protocol Number: 7502 Start Date*: 2015-02-23
    Sponsor Name:Kuopion yliopistollinen sairaala/Ensihoitokeskus
    Full Title: Intranasal fentanyl in pre-hospital analgesia
    Medical condition: Patients with trauma, musculoskeletal, stomach or back pain on numeric rating scale at least value 4
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-003846-10 Sponsor Protocol Number: MJIP1.0 Start Date*: 2024-05-02
    Sponsor Name:Fakultní nemocnice Plzeň
    Full Title: A pilot study comparing the haemodynamic effects and safety of an intravenous fluid bolus of 0.5M sodium lactate against 3% saline in patients with septic shock
    Medical condition: Septic shock fluid treatment
    Disease: Version SOC Term Classification Code Term Level
    26.0 10021881 - Infections and infestations 10040580 Shock septic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000958-36 Sponsor Protocol Number: RIDTS-Vers3-20Jan2016 Start Date*: 2016-08-18
    Sponsor Name:DIPARTIMENTO DI MEDICINA CLINICA E SPERIMENTALE
    Full Title: RIDTS Study - Rivaroxaban for the treatment of symptomatic Isolated Distal deep vein Thrombosis
    Medical condition: SYMPTOMATIC ISOLATED DISTAL DEEP VEIN THROMBOSIS
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10049915 Deep venous thrombosis distal LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001296-67 Sponsor Protocol Number: CBFU Start Date*: 2016-07-26
    Sponsor Name:ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE
    Full Title: DUAL ENERGY CONTRAST ENHANCED DIGITAL MAMMOGRAPHY PERFORMANCE EVALUATION IN COMPARISON OF CONVENTIONAL DIGITAL MAMMOGRAPHY, TOMOSINTESIS AND MR IMAGING IN WOMEN FOLLOW-UP FOR BREAST CARCINOMA
    Medical condition: WOMAN WITH BREAST CANCER
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10006206 Breast carcinoma NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001132-36 Sponsor Protocol Number: GOIRC-03-2016 Start Date*: 2016-10-03
    Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC)
    Full Title: A double-blind, placebo controlled, randomized multicenter Phase II Study evaluating Gemcitabine with or without Ramucirumab as II line treatment for advanced malignant pleural mesothelioma
    Medical condition: diffuse malignant pleural mesethelioma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10035605 Pleural mesothelioma malignant advanced LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001859-43 Sponsor Protocol Number: CA209-743 Start Date*: 2016-11-04
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase III, Randomized, Open Label Trial of Nivolumab in combination with Ipilimumab versus Pemetrexed with Cisplatin or Carboplatin as First Line Therapy in unresectable Pleural Mesothelioma
    Medical condition: Untreated unresectable Pleural Mesothelioma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) NL (Completed) BE (Completed) DE (Completed) FR (Completed) PL (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-001657-41 Sponsor Protocol Number: M15-531 Start Date*: 2016-12-01
    Sponsor Name:ABBVIE DEUTSCHLAND GMBH & CO. KG
    Full Title: A Phase 1b Dose Escalation Study Evaluating the Safety and Pharmacokinetics of Venetoclax in Combination with Azacitidine in Subjects with Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)
    Medical condition: Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028532 Myelodysplasia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002006-39 Sponsor Protocol Number: ESTER Start Date*: 2016-11-14
    Sponsor Name:ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE "LAZZARO SPALLANZANI"
    Full Title: Study on Efficacy and safety of an early proactive Switch To ElvitegraviR/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in patients with a primary HIV-1 infection
    Medical condition: Treatment of HIV infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002382-62 Sponsor Protocol Number: RNS60-ALS Start Date*: 2017-01-13
    Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
    Full Title: The effects of RNS60 on ALS biomarkers
    Medical condition: Amyotrophic Lateral Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    21.1 10029205 - Nervous system disorders 10052889 ALS LLT
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002036-32 Sponsor Protocol Number: C3441006(MDV3800-06) Start Date*: 2016-12-05
    Sponsor Name:Pfizer Inc.
    Full Title: TALAPRO 1: A PHASE 2, OPEN LABEL, RESPONSE RATE STUDY OF TALAZOPARIB IN MEN WITH DNA REPAIR DEFECTS AND METASTATIC CASTRATION RESISTANT PROSTATE CANCER WHO PREVIOUSLY RECEIVED TAXANE BASED CHEMOTHE...
    Medical condition: Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer Who Previously Received Taxane-Based Chemotherapy and Progressed on at Least 1 Novel Hormonal Agent (Enzalutamide and...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) NL (Completed) ES (Ongoing) FR (Completed) BE (Completed) GB (Completed) AT (Completed) DK (Prematurely Ended) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002498-36 Sponsor Protocol Number: CCN017 Start Date*: 2018-10-12
    Sponsor Name:National Institutes of Health - Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Full Title: Clinical Evaluation of Daily Application of Nestorone® (NES) and Testosterone (T) Combination Gel for Male Contraception
    Medical condition: As the clinical trial is intended to investigate a new contraceptive medicinal product, the trial subjects included are not characterized by a specific medical condition.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10065589 Male contraception PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002104-12 Sponsor Protocol Number: FP2CLI004 Start Date*: 2021-09-08
    Sponsor Name:Faron Pharmaceuticals Ltd.
    Full Title: A Phase I/II Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of the Clever-1 Antibody Bexmarilimab in Combination with Standard of Care Therapy in Patients with Myelody...
    Medical condition: -Myelodysplastic Syndrome -Chronic Myelomonocytic Leukemia -Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 1782  1783  1784  1785  1786  1787  1788  1789  1790  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 10 23:46:59 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA